ClinicalTrials.gg
CompletedNCT03372837Updated Apr 18, 2023

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of Rituximab in Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL, sponsored by SymBio Pharmaceuticals. Completed at 29 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by SymBio Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
119th of 211
40 · median 46
Started
2018
with 5 others
Phase 3
30 of 218
2 open now
Registered
162nd of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 119th largest by enrollment of the 211 interventional ones that give a count, is one of 6 that started in 2018, is one of 30 in phase 3, and was the 162nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

Read the detailed description

Primary Objective is to determine the efficacy, as measured by overall response rate on the basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m\^2/day on Day 2 and Day 3 in combination with rituximab at 375 mg/m\^2 on Day 1 of each 21-day cycle in patients with recurrent/relapsed diffuse large B-cell lymphoma.

03

Conditions studied

  • Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Keywords

  • Diffuse large B-cell lymphoma, rituximab, SyB L-0501, combination therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria Patients who satisfy all of the conditions listed below.

  1. Patients with histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) except for transformed lymphoma on the basis of World Health Organization (WHO) histological classification (4th ed., 2008).
  2. Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells.
  3. Patient with recurrent or DLBCL after R-CHOP-like theraphy as the firstline therapy.
  4. Patients with >1.5 cm in major axes.
  5. Patients who are expected to survive for at least 3 months.
  6. Patients aged 20 or above at the time is obtained.
  7. Patient with Performance Status (P.S.) 0-1.
  8. Patients with adequately maintained organ function.

Exclusion Criteria The study subject should be excluded if any one of the following condition exists.

  1. Patients who have been without treatment for less than 3 weeks after prior treatment.
  2. Patients who can be candidates for peripheral blood stem cell transplantation at the discretion of the investigator.
  3. Patients who received adequate prior treatments and did not respond to any of them.
  4. Patient who received prior chemotherapy 3 regimens or more.
  5. Patients with central nervous system (CNS) involvement or patients with clinical symptoms suggestive of CNS involvement.
  6. Patient with serious active infection.
  7. Patient with serious complication.
  8. Patient with complication or medical history of serious cardiac disease.
  9. Patient with serious gastrointestinal symptoms.
  10. Patient with malignant pleural effusion, pericardial effusion, or ascites retention.
  11. Patients positive for surface (HBs) antigen, virus (HCV) antibody, or antibody.
  12. Patient with serious bleeding tendency.
  13. Patient with a fever of 38.0°C or higher.
  14. Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema.
  15. Patients with active multiple primary cancer or patients with a history of other malignant cancer within the past 5 years, except for basal cell cancer of the skin, squamous cell cancer, or cervical cancer in situ.
  16. Patients with, or confirmed in the past to have had, hemolytic anemia.
  17. Patient who received bendamustin hydrochloride in the past.
  18. Patients who received cytokine preparation such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 2 weeks before the examination at registration for this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    SyB L-0501

    The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule. SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.

    Drug: Rituximab

Interventions

  • The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Complete Response (CR) + Partial Response (PR) Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007)

    Time frame: up to 30 weeks

Secondary outcomes

  1. Complete Response (CR) Rate

    Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007)

    Time frame: up to 30 weeks

  2. Progression Free Survival (PFS)

    PFS = day of the first PFS event - day of start of study treatment + 1

    Time frame: up to 30 weeks

  3. Duration of Response (DOR)

    DOR is the period from the date of achieving CR, or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% Confidence Interval (CI ) were calculated using Greenwood's formula.

    Time frame: up to 30 weeks

  4. Overall Survival (OS)

    Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula.

    Time frame: up to 30 weeks.

07

Study locations

29 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Toyoake, Aichi, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Shibukawa, Gunma, Japan
  • Research Site
    Ōta, Gunma, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Isehara, Kanagawa, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Osakasayama, Osaka, Japan
  • Research Site
    Izumo, Shimane, Japan
  • Research Site
    Mibu, Tochigi, Japan
  • Research Site
    Shimotsuke, Tochigi, Japan
  • Research Site
    Chuo-ku, Tokyo, Japan
  • Research Site
    Koto-ku, Tokyo, Japan
  • Research Site
    Shibuya-ku, Tokyo, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Fukushima, Japan
  • Research Site
    Ibaraki, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Nagasaki, Japan
  • Research Site
    Okayama, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Yamagata, Japan
08

References and documents

Publications

  • Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol. 2022 May;101(5):979-989. doi: 10.1007/s00277-022-04801-2. Epub 2022 Mar 4. PubMed 35244756 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2019, 23 months.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 23 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2017
First posted
Dec 14, 2017
StartActual
Jan 15, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03372837
Responsible party
Sponsor
First posted
Dec 14, 2017
Start date
Jan 15, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Apr 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion